

Merck & Co. Inc.  
Form 8-K  
October 01, 2013

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) October 1, 2013 (September 30, 2013)

Merck & Co., Inc.  
(Exact Name of Registrant as Specified in Its Charter)

New Jersey  
(State or Other Jurisdiction of Incorporation)

1-6571  
(Commission File Number)  
One Merck Drive, PO Box 100, Whitehouse Station, NJ  
(Address of Principal Executive Offices)  
Registrant's Telephone Number, Including Area Code

22-1918501  
(I.R.S. Employer Identification No.)  
08889-0100  
(Zip Code)  
(908) 423-1000

Not Applicable  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

Item 2.05. Costs Associated with Exit or Disposal Activities.

(a), (b), (c) and (d) On September 30, 2013, Merck & Co., Inc. (the “Company”) committed to a new global restructuring program (the “2013 Restructuring Program”) as part of a global initiative to sharpen its commercial and research and development focus. As part of the new program, the Company expects to reduce its total workforce by approximately 8,500 positions. These workforce reductions will primarily come from the elimination of positions in sales, administrative and headquarters organizations, as well as research and development. The Company will also reduce its global real estate footprint and continue to improve the efficiency of its manufacturing and supply network.

The actions under the 2013 Restructuring Program are expected to be substantially completed by the end of 2015 with the cumulative pretax costs estimated to be approximately \$2.5 billion to \$3.0 billion. The Company expects to record charges of approximately \$900 million to \$1.1 billion related to this program in 2013, a majority of which will be recorded in the third quarter. The Company estimates that approximately two-thirds of the cumulative pretax costs will result in cash outlays, primarily related to employee separation expense. Approximately one-third of the cumulative pretax costs are non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested.

The Company expects the actions under the 2013 Restructuring Program to result in annual net cost savings of approximately \$2.0 billion by the end of 2015. The Company anticipates that the actions under the 2013 Restructuring Program, combined with remaining actions under previously announced restructuring programs, will result in annual net cost savings of \$2.5 billion by the end of 2015 compared with full-year 2012 expense levels.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits  
Exhibit 99.1 Press release issued October 1, 2013

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Merck & Co., Inc.

Date: October 1, 2013

By: /s/ Katie E. Fedosz  
KATIE E. FEDOSZ  
Senior Assistant Secretary

---

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press release issued October 1, 2013